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Background. A multi-centre, four-arm trial (the PACE trial) found that rehabilitative cognitive behaviour therapy
(CBT) and graded exercise therapy (GET) were more eﬀective treatments for chronic fatigue syndrome (CFS) than
specialist medical care (SMC) alone, when each was added to SMC, and more eﬀective than adaptive pacing therapy
(APT) when added to SMC. In this study we compared how many participants recovered after each treatment.
Method. We deﬁned recovery operationally using multiple criteria, and compared the proportions of participants
meeting each individual criterion along with two composite criteria, deﬁned as (a) recovery in the context of the trial
and (b) clinical recovery from the current episode of the illness, however deﬁned, 52 weeks after randomization. We
used logistic regression modelling to compare treatments.
Results. The percentages (number/total) meeting trial criteria for recovery were 22% (32/143) after CBT, 22%
(32/143) after GET, 8% (12/149) after APT and 7% (11/150) after SMC. Similar proportions met criteria for clinical
recovery. The odds ratio (OR) for trial recovery after CBT was 3.36 [95% conﬁdence interval (CI) 1.64–6.88] and for
GET 3.38 (95% CI 1.65–6.93), when compared to APT, and after CBT 3.69 (95% CI 1.77–7.69) and GET 3.71 (95% CI
1.78–7.74), when compared to SMC (p values f0.001 for all comparisons). There was no signiﬁcant diﬀerence
between APT and SMC. Similar proportions recovered in trial subgroups meeting diﬀerent deﬁnitions of the illness.
Conclusions. This study conﬁrms that recovery from CFS is possible, and that CBT and GET are the therapies most
likely to lead to recovery.
Received 16 August 2012 ; Revised 14 December 2012 ; Accepted 17 December 2012
Key words : Chronic fatigue syndrome, cognitive behaviour therapy, graded exercise therapy, randomized control trial,
recovery.
Introduction
Chronic fatigue syndrome (CFS) is a disabling dis-
order of unknown cause, with a prevalence of between
0.4% and 2.5% in the UK population (Prins et al. 2006).
Myalgic encephalomyelitis (ME) is thought by some
researchers to be the same disorder and by others as
diﬀerent with separate diagnostic criteria (Prins et al.
2006; NICE, 2007). Common symptoms of CFS include
fatigue, painful muscles and joints, poor concentration
and sleep disturbance ; these symptoms do not remit
with rest and are made worse by activity.
Established treatments for CFS include the re-
habilitative therapies of cognitive behaviour therapy
(CBT) and graded exercise therapy (GET) (NICE,
2007). Several meta-analyses of these therapies in-
dicate moderate beneﬁt from these treatments
(Edmonds et al. 2004; Malouﬀ et al. 2008; Price et al.
2008; Castell et al. 2011). The recently published PACE
trial found that CBT and GET were more eﬀective in
reducing both fatigue and physical disability than
adaptive pacing therapy (APT), when each was added
to specialist medical care (SMC), and more eﬀective
than SMC alone (White et al. 2011).
Although the PACE trial found that many patients
improved with CBT and GET, the question of how
many patients recovered remains unanswered. We
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know that recovery from CFS without treatment is
reported to be uncommon; a systematic review found
that a median (range) of only 7% (0–48%) recovered
over time (Cairns & Hotopf, 2005). We also know from
a previous study that 24% of 25 patients rated them-
selves as ‘recovered’ 5 years after CBT (Deale et al.
2001) and that when applying more detailed, oper-
ationalized criteria (no longer fatigued, able to resume
activities, and a perception of health and fatigue
similar to that of a healthy person), 23% of 96 patients
were rated as ‘recovered’ immediately after a course
of CBT (Knoop et al. 2007). However, there have
been no published reports comparing the proportions
recovered after CBT with those achieved after other
treatments.
Before we can determine the proportions recovered
we need an operational deﬁnition of recovery itself.
An ideal deﬁnition remains uncertain, as is the case for
other conditions, such as low back pain (Kamper et al.
2011). Measurement of recovery could involve many
domains. Within the trial context these could include:
no longer meeting trial eligibility criteria, not having
signiﬁcant symptoms, not being disabled by the ill-
ness, and regarding one’s health as having improved
considerably. Within a clinical context, the additional
criteria of not meeting alternative deﬁnitions of CFS
and ME could also be applied (Sharpe et al. 1991;
Tyrrell, 1994 ; Reeves et al. 2003).
Creating criteria for recovery from domains that
are measured on a continuum requires the setting of
operational thresholds based on population studies or
trial eligibility criteria (Powell et al. 2004; Knoop et al.
2007; Malouﬀ et al. 2008). In this context it is important
to note that recovery does not mean being free of all
symptoms; population studies show that the average
person in the UK reports a mean of four symptoms
in any 2-week period (McAteer et al. 2011). The three
most common symptoms reported were fatigue,
headache and joint pain; symptoms consistent with
CFS (McAteer et al. 2011). Recovery may be taken to
imply that the patient has made a transition from
ill health to remission and also is at little risk of re-
currence (Nisenbaum et al. 2003). Although we can
measure remission, we cannot be certain of the risk of
recurrence without long-term follow-up; we therefore
use the term ‘recovery’ in this paper to mean recovery
from the current episode of the illness.
The aims of this study were to : (a) deﬁne oper-
ationalized criteria for recovery on relevant domains,
(b) calculate the proportions of trial participants
meeting each of these individual criteria in each
treatment arm, (c) calculate the proportion of trial
participants meeting all the recovery criteria to pro-
vide a comprehensive and conservative deﬁnition
of recovery in each treatment arm, (d) compare the
proportions meeting both trial and clinical recovery
criteria between the treatment arms, and (e) compare
these proportions within each of the two subgroups
of participants in the trial, which met the international
deﬁnition of CFS and the London deﬁnition of ME
(Tyrrell, 1994). As CBT and GET were the most eﬀec-
tive treatments in the trial, we hypothesized that
they would also be associated with greater propor-
tions of recovered individuals at the 52-week primary
end-point than either APT or SMC alone.
Method
The PACE trial recruited 641 participants from six
secondary care CFS clinics in England and Scotland,
allocated randomly to one of four treatment groups,
with a ﬁnal follow-up 52 weeks after randomization
(White et al. 2007, 2011). All participants met the
Oxford criteria for CFS (Sharpe et al. 1991). The four
trial treatment arms were : SMC alone delivered by
specialist CFS doctors, SMC plus APT delivered by
occupational therapists, SMC plus CBT delivered
by clinical psychologists, and SMC plus GET delivered
by physiotherapists. Specialist doctors gave an expla-
nation of why participants were ill and general advice
about managing the illness. They also prescribed
medicines to help with symptoms such as insomnia
and pain, or advised general practitioners (GPs) on
which medicine was appropriate. If a participant was
randomized to this treatment alone, they were also
encouraged to use self-help management that made
most sense to them. APT involved carefully matching
activity levels to the amount of energy available.
Therapists worked with participants in this group to
help monitor activity and symptoms, aiming to im-
prove quality of life and create the best conditions for
natural remission. CBT involved examining how
thoughts, behaviour and symptoms interact with each
other. Between therapy sessions, participants in this
group were encouraged to try out new ways of coping
with their illness. GET involved gradually increasing
physical activity to improve ﬁtness and get the body
used to activity again. Therapists helped participants
in this group to work out a basic activity routine and
slowly build up the amount of exercise (White et al.
2007, 2011).
Domains, measures and criteria for deﬁning recovery
We chose domains for deﬁning recovery on the basis
of the previous literature and the measures available
from the trial. The thresholds deﬁning our criteria for
recovery on each domain were based either on popu-
lation normal ranges, case deﬁnitions or trial entry
criteria. We changed three of the thresholds for
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measuring recovery from our original protocol (White
et al. 2007) before the analysis, as explained below.
Fatigue : the Chalder Fatigue Questionnaire (CFQ)
The 11-item CFQ measured the severity of sympto-
matic fatigue, rated by the participant, and was one of
the primary outcomes of the trial (Chalder et al. 1993).
The respondent chose from one of four answers (‘ less
than usual ’, ‘no more than usual ’, ‘more than usual ’
and ‘much more than usual ’) to each item, scores be-
ing 0, 1, 2 or 3, with a maximum score of 33 indicating
severe fatigue. We changed our original protocol’s
threshold score for being within a normal range from
a binary score off3 out of 11 (White et al. 2007), which
represented a screening threshold for abnormal fati-
gue from a small primary care study (Chalder et al.
1993), following the publication of a much larger study
of fatigue in adults in a representative population
sample of patients registered with a GP from South
East England (Cella & Chalder, 2010). This showed
a population mean (S.D.) Likert score of 14.2 (4.6) out
of a maximum score of 33. We therefore considered a
score of 18 (highest integral score below the mean plus
1 s.D.) or less as within the normal range for fatigue.
Physical function : the 36-Item Short-Form Health Survey
(SF-36) physical function subscale
The SF-36 physical function subscale, rated by the
participants, was the other primary outcome from the
trial (McHorney et al. 1993). The scale asks about 10
aspects of physical function, such as the ability to walk
100 m, with three possible answers : not limited, lim-
ited a little, and limited a lot. This provides a derived
score that ranges from worst (0) to best possible func-
tion (100). We changed our original protocol’s thresh-
old score for being within a normal range on this
measure from a score of o85 to a lower score as that
threshold would mean that approximately half the
general working age population would fall outside the
normal range. The mean (S.D.) scores for a demo-
graphically representative English adult population
were 86.3 (22.5) for males and 81.8 (25.7) for females
(Bowling et al. 1999). We derived a mean (S.D.) score
of 84 (24) for the whole sample, giving a normal range
of 60 or above for physical function.
CFS case deﬁnition : Oxford criteria
This was the deﬁnition of CFS used to deﬁne eligibility
for participation in the trial. Research assessors judged
whether participants still met Oxford criteria for CFS
at 52 weeks ; speciﬁcally they determined if : (1) fatigue
was the main symptom, (2) it was of deﬁnite onset
and not lifelong, (3) fatigue was severe, disabling and
aﬀected physical and mental function, and (4) fatigue
had persisted for 6 months or more and was present
50% of the time (Sharpe et al. 1991). To satisfy the third
criterion for severity of fatigue and disability, partici-
pants had to meet trial entry thresholds for fatigue
(a binary score of o6 out of 11 on the CFQ) and ab-
normal levels of physical function (a score off65 out
of 100 on the SF-36 physical function subscale) (White
et al. 2007).
CFS case deﬁnition : the International (Centers for Disease
Control and Prevention, CDC) criteria
The research assessor used participant ratings to judge
whether participants met the International (CDC)
criteria for CFS at 52 weeks (Reeves et al. 2003), which
included: (1) severe chronic fatigue for at least
6 months with other known medical conditions
(whose manifestation includes fatigue) excluded by
clinical diagnosis ; and (2) concurrently have four
or more of the following symptoms: post-exertional
malaise, impaired memory or concentration, un-
refreshing sleep, muscle pain, multi-joint pain without
redness or swelling, tender cervical or axillary lymph
nodes, sore throat, headache. For the purposes of this
study, the four or more symptoms needed to be pres-
ent within the previous week of the assessment date,
rather than the previous 6 months (Reeves et al. 2003).
To meet the ﬁrst criterion for severity, participants had
to have abnormal levels of fatigue, which we took to
be the trial entry eligibility criteria for the CFQ, and
abnormal levels of physical function (as above) (White
et al. 2007).
ME case deﬁnition : the London criteria
Research assessors judged whether participants met
the London criteria for ME at 52 weeks (Tyrrell, 1994).
Speciﬁcally, these criteria included: (1) exercise-
induced fatigue precipitated by trivially small exer-
tion, (2) impairment of short-term memory and loss of
powers of concentration, (3) ﬂuctuations of symptoms
usually precipitated by physical or mental exertion,
(4) symptoms present for at least 6 months, and (5) no
‘primary’ depressive illness and no anxiety disorder
present (which we interpreted as no co-morbid mood
disorder of any kind). To standardize thresholds for
severity with other case deﬁnitions, participants also
had to meet trial entry eligibility criteria for the CFQ
and abnormal levels of physical function (as above)
(White et al. 2007).
Overall change in health : the Clinical Global Impression
(CGI) change score
The self-rated CGI change score (range 1–7) provided
a participant-rated global measure of overall health
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change, not just change in CFS (Guy, 1976). We con-
sidered scores of 1 (‘very much better ’) or 2 (‘much
better ’) as evidence of the process of recovery, rather
than our original protocol threshold of a score of
1 only, because we considered that participants rating
their overall health as ‘much better ’ represented the
process of recovery. The CGI change scale was also
rated by the SMC doctor at the 52-week review.
These scores were used as imputed scores when the
participant-rated CGI score was missing at 52 weeks
(n=22).
Composite deﬁnitions of recovery
We operationalized two composite deﬁnitions of re-
covery : (1) trial recovery from CFS, and (2) clinical
recovery from the illness, however it was deﬁned. To
provide a deﬁnition of trial recovery, we calculated a
hierarchical, cumulative deﬁnition that included the
following domains mentioned earlier : normal range
in fatigue, normal range in physical function, not
meeting the Oxford case deﬁnition of CFS, and CGI
scores of 1 or 2 (‘very much’ or ‘much’ better). To
fulﬁl the criteria for clinical recovery from the illness,
participants had to meet all the criteria for trial-
deﬁned recovery (described earlier), in addition to not
meeting either the International (CDC) criteria for CFS
or the London criteria for ME.
Analysis
We reported descriptive statistics (percentage and
frequency) in each treatment arm for each individual
domain of recovery. We then gave the results of a
cumulative hierarchy of the proportions meeting
domains of trial recovery in the order of : normal
ranges for both the fatigue and physical function
scores, not meeting the Oxford criteria for CFS, and
the clinical global impression positive change scores
(1 or 2). The cumulative hierarchy of clinical recovery
was then applied as the trial deﬁnition of recovery
combined with not meeting criteria for either the
International (CDC) deﬁnition of CFS or the London
criteria for ME. We calculated the number needed to
treat (NNT) for one extra participant to recover by
dividing 100 by the proportion recovering after either
CBT or GET minus the proportion recovering after
SMC, rounded up to the nearest whole number.
To examine recovery in participants who also met
either the International (CDC) deﬁnition of CFS or
the London deﬁnition of ME at entry to the trial, we
applied the same cumulative hierarchy of criteria in
these subgroups. We then used logistic regression to
compare the odds of recovery between trial arms,
using the originally hypothesized comparison groups:
APT v. SMC, CBT v. SMC, GET v. SMC, APT v. CBT
and APT v. GET (White et al. 2011). Resulting odds
ratios (ORs) and 95% conﬁdence intervals (CIs) were
adjusted for the stratiﬁcation variables of centre,
meeting International (CDC) criteria at baseline,
meeting the London deﬁnition of ME at baseline, and
having a depressive illness at baseline. Interaction
terms for trial arm by meeting either CFS or ME
criteria at baseline were used to calculate the odds of
recovery in (1) the subgroup meeting International
(CDC) criteria at baseline and (2) the subgroup meet-
ing the London deﬁnition of ME at baseline.
Results
We studied 640 participants (excluding one partici-
pant who withdrew consent after the study). The
mean (S.D.) age was 38 (12) years, 77% were female,
and 93% were Caucasian. All participants met the
Oxford criteria for CFS; 67% of participants also met
the International (CDC) criteria for CFS and 51% met
the London criteria for ME (White et al. 2011). The
median (interquartile range, IQR) duration of illness
was 32 (16–68) months, 47% had a co-morbid psychi-
atric condition at randomization (33% depressive
disorder). By 52 weeks, only 33 (5%) were missing
primary outcome data, with no signiﬁcant diﬀerence
between treatment groups.
Table 1a shows the individual criteria for recovery
at 52 weeks. Whatever the domain, the largest pro-
portions of participants recovering had received
either CBT or GET. Overall, the largest proportions of
participants meeting criteria for recovery were those
who no longer met criteria for ME, followed by the
Internationally deﬁned criteria for CFS, and then the
Oxford-deﬁned criteria for CFS.
Table 1b shows the hierarchical, cumulative deﬁni-
tions for both trial and clinical recovery. As each
additional criterion was added, the proportions meet-
ing criteria for recovery generally were reduced. For
all the criteria applied, the largest proportions of re-
covered participants were found in those who had
received either CBT or GET. Some data were missing
for 6% of those receiving APT and SMC and 11% for
those in receipt of CBT and GET. The NNT for one
extra participant to achieve trial recovery was 7 for
both CBT and GET.
The proportions meeting criteria for clinical re-
covery from the illness were very similar to the pro-
portions meeting the trial deﬁnition for recovery
(Table 1b). Although it seemed that slightly smaller
proportions had recovered from the illness as a whole,
when the criterion ‘not meeting the London criteria for
ME’ was applied, we found that the diﬀerences were
due to missing data rather than to change in recovery
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status. For this reason, we made a post-hoc decision to
model the more complete data set of those meeting the
trial deﬁnition of recovery rather than the illness
deﬁnition of recovery.
Table 2 shows the proportions who met the trial
deﬁnition of recovery in subgroups that met alter-
native deﬁnitions of CFS or ME at baseline. The
pattern of results was very similar to those for all
participants ; CBT and GET were associated with the
largest proportions of participants recovered.
Table 3 shows that odds of trial deﬁnitions of re-
covery after either CBT or GET were more than three
times those after either APT or SMC. There was no
signiﬁcant diﬀerence between APT and SMC. A simi-
lar pattern of diﬀerences was observed in the two
subgroups that met the International (CDC) deﬁnition
for CFS (interaction term p value=0.77) and in those
who met the London criteria for ME at entry
(interaction term p value=0.76).
Discussion
We found that CBT and GET were both signiﬁcantly
more likely than APT and SMC to be associated with
recovery at 52 weeks, even when using a conservative
deﬁnition of recovery. Between a ﬁfth and a quarter
Table 1. Participants, % (n/total), meeting criteria for recovery
Domains and measures APT (159) CBT (161) GET (160) SMC (160)
(a) Individual criteria
Fatigue
Within CFQ normal range 22 (34/153) 41 (60/148) 33 (51/154) 21 (32/152)
Physical function
Within SF-36-PF normal range 35 (53/153) 52 (77/148) 53 (81/154) 41 (62/152)
Both fatigue and function
Within both CFQ and SF-36-PF
normal ranges
16 (25/153) 30 (44/148) 28 (43/154) 15 (22/152)
Case criteria
CDC criteria not met 49 (74/150) 67 (97/144) 65 (93/144) 51 (76/149)
Oxford criteria not met 43 (64/149) 54 (77/143) 56 (81/144) 41 (62/150)
London ME criteria not met 68 (100/147) 76 (107/140) 77 (106/138) 66 (97/148)
Overall health change
CGI 1 or 2 30 (48/158) 40 (62/154) 40 (63/156) 25 (40/158)
APT CBT GET SMC
(b) Composite criteria for both trial and clinical recovery (combined hierarchically)
Cumulative criteria for trial recovery
Both CFQ and SF-36-PF in normal
range
16 (25/153) 30 (44/148) 28 (43/154) 15 (22/152)
And Oxford criteria not met 15 (23/149) 28 (40/143) 28 (41/144) 14 (21/150)
And CGI 1 or 2 (95% CI) 8 (12/149)
(4–14)
22 (32/143)
(16–30)
22 (32/143)
(16–30)
7 (11/150)
(4–13)
Additional criteria for clinical recovery
And International (CDC) CFS criteria
not met
8 (12/149) 22 (32/143) 22 (32/143) 7 (11/149)
And London ME criteria not met
(95% CI)
8 (12/147)
(4–14)
21 (29/139)
(14–29)
21 (29/138)
(15–29)
7 (11/147)
(4–13)
CFQ, Chalder Fatigue Questionnaire ; SF-36-PF, Short Form 36-item measure of physical function ; CGI, Clinical Global
Impression change measure ; APT, adaptive pacing therapy ; CBT, cognitive behaviour therapy ; GET, graded exercise therapy ;
SMC, specialist medical care ; CDC, Centers for Disease Control and Prevention ; CFS, chronic fatigue syndrome ; ME, myalgic
encephalomyelitis ; CI, conﬁdence interval.
Normal range for CFQ wasf18/33 ; normal range for SF-36-PF waso60/100.
Values given as % (n/total).
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of participants were recovered by 52 weeks after
either CBT or GET, with an NNT of seven. A similar
pattern was seen in the two subgroups meeting
alternative deﬁnitions for CFS and ME at entry into
the trial.
The main limitation of this analysis is the absence of
a generally agreed measure of recovery. We addressed
this by using multiple domains of health and dis-
ability. The domains chosen and the criteria for re-
covery on each were deﬁned before we undertook the
analysis. Alternative domains could have been used,
such as return to work or objective measures of
physical activity. Return to work is not, however, an
appropriate measure of recovery if the participant was
not working before their illness and is inﬂuenced by
other factors such as the job market. Objective meas-
ures of physical activity have been found previously to
correlate poorly with self-reported outcomes (Wiborg
et al. 2010), which may be related to the ﬁnding that
activity patterns in CFS patients are heterogeneous,
with only a minority being pervasively passive (van
der Werf et al. 2001). We did not include any measures
of mood in our domains of recovery as mood is not
part of the deﬁnition of the illness.
The amount of missing outcome data was greater
after CBT and GET than after APT and SMC, but the
percentages missing were small enough not to warrant
sensitivity analyses, particularly because all but 33
(5%) participants contributed some data. The preva-
lence of the case-level International (CDC) deﬁnition
of CFS may have been inaccurate because we only
examined for accompanying symptoms in the pre-
vious week, not the previous 6 months. The assess-
ments of caseness (CDC, London and Oxford criteria)
relied on a mixture of self-ratings and research assist-
ant assessments, making some observer bias possible.
We changed some of the thresholds for measuring
recovery from those of the original protocols (White
et al. 2007) ; we made the changes before analysis
and to more accurately reﬂect recovery. Our ﬁnding
that only 7% recovered after the minimal treatment
of SMC, exactly the same proportion as the median
recovery rate found without treatment (Cairns &
Hotopf, 2005), supports these revised thresholds.
Table 3. Comparison of odds for composite trial recovery adjusted for baseline characteristics
All participants
Met international (CDC)
criteria at baseline
Met London ME criteria at
baseline
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
CBT v. APT 3.36 (1.64–6.88) 0.001 2.73 (1.16–6.44) 0.022 2.72 (1.09–6.78) 0.032
CBT v. SMC 3.69 (1.77–7.69) <0.001 4.14 (1.56–11.00) 0.004 3.18 (1.23–8.23) 0.017
GET v. APT 3.38 (1.65–6.93) 0.001 2.96 (1.27–6.90) 0.012 2.52 (1.01–6.28) 0.048
GET v. SMC 3.71 (1.78–7.74) <0.001 4.50 (1.72–11.79) 0.002 2.95 (1.14–7.61) 0.026
APT v. SMC 1.10 (0.47–2.58) 0.83 1.52 (0.52–4.46) 0.450 1.17 (0.40–3.43) 0.77
CBT, Cognitive behaviour therapy ; APT, adaptive pacing therapy ; SMC, specialist medical care ; GET, graded exercise
therapy ; CDC, Centers for Disease Control and Prevention ; ME, myalgic encephalomyelitis ; OR, odds ratio ; CI, conﬁdence
interval.
International (CDC) interaction p=0.77 ; London ME interaction p=0.76.
Table 2. Composite criteria for trial recovery in subgroups meeting alternative deﬁnitions
of CFS or ME at baseline
APT CBT GET SMC
All participants 8 (12/149) 22 (32/143) 22 (32/143) 7 (11/150)
International (CDC)
criteria
9 (9/102) 19 (17/89) 22 (20/93) 6 (6/98)
London ME criteria 11 (8/75) 21 (15/70) 21 (16/75) 10 (7/73)
CFS, Chronic fatigue syndrome ; ME, myalgic encephalomyelitis ; APT, adaptive
pacing therapy ; CBT, cognitive behaviour therapy ; GET, graded exercise therapy ;
SMC, specialist medical care ; CDC, Centers for Disease Control and Prevention.
Values given as % (n/total).
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Finally, we cannot be sure that recovery was sustained
beyond the assessment at 52 weeks.
How do these results compare with previous stud-
ies? We are not aware of any previous studies that
have compared comprehensively deﬁned recovery
between diﬀerent treatments. Two studies of recovery
in adults after CBT found similar proportions in
recovery : 23% and 24% (Deale et al. 2001; Knoop et al.
2007), compared with 22% in the PACE trial. One of
these studies had a 5-year follow-up period rather
than the 1 year of our study, and the majority had
received further treatment in those extra 4 years, all
patients being treated at one specialist CFS centre
(Deale et al. 2001). The other study used similar criteria
and domains for recovery (Knoop et al. 2007), but the
deﬁnition for normal range used was the more liberal
population mean ¡2 s.D. rather than the more con-
servative 1 S.D. that we used; the treatment was deliv-
ered by therapists in one specialist CFS centre and
outside of a trial setting. A meta-analysis of random-
ized controlled trials of CBT for CFS reported that a
mean of 50% of the patients improved to the point of
no longer being clinically fatigued (Malouﬀ et al. 2008).
A 2-year follow-up study after an educational inter-
vention to encourage GET found that 55% of the trea-
ted patients no longer fulﬁlled trial criteria for CFS
(Powell et al. 2004). Although not directly comparable,
we found that 41% and 33% were within the popu-
lation range for fatigue after CBT and GET respect-
ively, although these proportions drop further when
added to functional improvement ; 54% and 56% of
participants no longer met the trial entry (Oxford) case
deﬁnition for CFS after CBT and GET. Our ﬁnding that
22–56% of participants met various composite or
single criteria for recovery or improvement a year after
starting either CBT or GET is therefore consistent
with previously published studies. The NNT of 7 for
recovery after both CBT and GET is within the range
of the eﬀects found for drug treatments in both general
medical and psychiatric conditions (Leucht et al. 2012).
Although only 22% recovered after either CBT or GET,
if diﬀerent participants recovered after CBT than
after GET, then the proportion recovering after either
treatment would be larger than 22%, but not larger
than 39%. Recovery after CBT may be better in ado-
lescents (Nijhof et al. 2012). The 7% and 8% recovered
after both APT and SMC were similar to the 7% re-
ported in a systematic review after no treatment, sug-
gesting a lack of eﬃcacy of these treatments (Cairns &
Hotopf, 2005).
The proportions recovered in each treatment arm
were similar in the subgroups meeting alternative de-
ﬁnitions of CFS and ME, implying that these ﬁndings
generalize to diﬀerent deﬁnitions of CFS and ME.
Patients who have either CFS or ME characterized by a
principal complaint of fatigue, and who are attending
out-patient clinics, should therefore be oﬀered either
CBT or GET to provide the best chance of recovery
with these treatments.
As a little more than a ﬁfth of participants treated
with CBT or GET had recovered a year after starting
treatment, we still need to consider ways of enhancing
the eﬀectiveness of these treatments. Two ways of
doing this could be to increase the number of sessions
above that oﬀered in the PACE trial (15 sessions), be-
cause a recent meta-analysis found that higher num-
bers of sessions improved eﬃcacy (Castell et al. 2011),
or enhancing delivery of therapy, such as over the in-
ternet (Nijhof et al. 2012). Another approach may be to
oﬀer both CBT and GET in series. A diﬀerent approach
would be to identify the factors that mediate the eﬀect
of these treatments, with the aim of optimizing their
eﬀectiveness ; the mediation analysis of the PACE data
is under way. CFS is a heterogeneous condition and
we need to ﬁnd ways of identifying subgroups that
respond best to each type of therapy (Cella et al. 2011).
Finally, we also need to develop additional forms of
treatment.
In conclusion, recovery from CFS is more likely to
occur when CBT or GET is added to SMC than after
adding APT or giving SMC by itself. The relatively
small proportion of recovered patients may reﬂect the
heterogeneity of CFS; it should also spur us on both to
enhance currently available therapies and to develop
new and better treatments.
Appendix. The PACE Trial Management Group
The PACE Trial Management Group consisted
of the authors of this paper plus (in alphabetical
order) : B. J. Angus, H. Baber, J. Bavinton, M. Burgess,
L. V. Clark, D. L. Cox, J. C. DeCesare, E. Feldman,
P. McCrone, G. Murphy, M. Murphy, H. O’Dowd,
T. Peto, L. Potts, R. Walwyn, D. Wilks.
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